zotarolimus

This page covers all zotarolimus drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR.

Targets

Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR

Phase 3 pipeline (1)

• ZOTAROLIMUS · Immunology
  Zotarolimus works by binding to the FKBP1A protein, which is involved in the activation of calcineurin and subsequent T-cell activation.

Patent intelligence

• zotarolimus patent landscape — aggregated cliff calendar, attackable patents, originator estates